The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians

Juan-Sebastian Franco, Nicolás Molano-González, Monica Rodríguez-Jiménez, Yeny Acosta-Ampudia, Rubén D Mantilla, Jenny Amaya-Amaya, Adriana Rojas-Villarraga, Juan-Manuel Anaya

Resultado de la investigación: Contribución a una revistaArtículo

19 Citas (Scopus)

Resumen

OBJECTIVES: To examine the prevalence and associated factors related to the coexistence of antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) in a cohort of Colombian patients with SLE, and to discuss the coexistence of APS with other autoimmune diseases (ADs).

METHOD: A total of 376 patients with SLE were assessed for the presence of the following: 1) confirmed APS; 2) positivity for antiphospholipid (aPL) antibodies without a prior thromboembolic nor obstetric event; and 3) SLE patients without APS nor positivity for aPL antibodies. Comparisons between groups 1 and 3 were evaluated by bivariate and multivariate analysis.

RESULTS: Although the prevalence of aPL antibodies was 54%, APS was present in just 9.3% of SLE patients. In our series, besides cardiovascular disease (AOR 3.38, 95% CI 1.11-10.96, p = 0.035), pulmonary involvement (AOR 5.06, 95% CI 1.56-16.74, p = 0.007) and positivity for rheumatoid factor (AOR 4.68, 95%IC 1.63-14.98, p = 0.006) were factors significantly associated with APS-SLE. APS also may coexist with rheumatoid arthritis, Sjögren's syndrome, autoimmune thyroid diseases, systemic sclerosis, systemic vasculitis, dermatopolymyositis, primary biliary cirrhosis and autoimmune hepatitis.

CONCLUSIONS: APS is a systemic AD that may coexist with other ADs, the most common being SLE. Awareness of this polyautoimmunity should be addressed promptly to establish strategies for controlling modifiable risk factors in those patients.

Idioma originalInglés estadounidense
Páginas (desde-hasta)e110242
PublicaciónPLoS One
Volumen9
N.º10
DOI
EstadoPublicada - oct 24 2014

    Huella digital

Citar esto